Ruxolitinib targets DCs: For better or worse?

Blood

Volumn 122, Issue 7, 2013, Pages 1096-1097

  Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; RUXOLITINIB; JANUS KINASE; PYRAZOLE DERIVATIVE;

ANTIGEN SPECIFICITY; CELL ACTIVATION; CELL MIGRATION; CELLULAR IMMUNITY; DENDRITIC CELL; DOSE RESPONSE; DRUG EFFECT; HUMAN; IN VIVO STUDY; INHIBITION KINETICS; MONOCYTE; MYELOFIBROSIS; PRIORITY JOURNAL; SHORT SURVEY; T LYMPHOCYTE; TARGET CELL; TISSUES; VIRAL CLEARANCE; ANIMAL; ANTIGEN PRESENTING CELL; CYTOTOXIC T LYMPHOCYTE; DRUG ANTAGONISM; NOTE;

ANIMALS; ANTIGEN-PRESENTING CELLS; DENDRITIC CELLS; HUMANS; JANUS KINASES; PYRAZOLES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84887149115     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-07-509612     Document Type: Short Survey

References (9)

1. Heine A, Held SA, Daecke S.N., et al. The JAKinhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013; 122(7): 1192-1202.
2. Merad M, Sathe P, Helft J., Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol. 2013; 31: 563-604.
3. Tefferi A, Vaidya R, Caramazza D., Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011; 29(10): 1356-1363.
4. Pardanani A, Vannucchi AM, Passamonti F, Cervantes F., Barbui T, Tefferi A. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia. 2011; 25(2): 218-225.
5. Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene. 2013; 32(21): 2601-2613.
6. Verstovsek S, Kantarjian H, Mesa R.A., et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010; 363(12): 1117-1127.
7. Dai T, Friedman EW, Barta SK. Ruxolitinib Withdrawal Syndrome Leading to Tumor Lysis [published online ahead of print June 10, 2013]. J Clin Oncol.
8. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011; 29(7): 789-796.
9. Pardanani A, Laborde RR, Lasho T.L., et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013; 27(6): 1322-1327.